**Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMs), Biosimilars, Generics & Vaccines**

Description: PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 333 tables & figures. The Indian pharmaceutical market (IPM) is presented as follows:

- By Company (e.g., CIPLA, SUN PHARMA, RANBAXY, PIRAMAL, ZYDUS CADILA, MANKIND, LUPIN)
- By Segment (FORMULATIONs, APIs, BIOSIMILARs, CRAMS, GENERICs, VACCINES)
- By Therapeutic Area (e.g., Cardiovascular, Diabetes, Cancer, Respiratory)
- By Disease Category (Acute, Chronic)

A wealth of financial information is provided including:

- Up-to-date company financials, sales & revenue figures
- India GDP, economic growth, export (bulk drug, formulations) figures
- Indian health expenditure as a function of GDP
- Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
- Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)

SWOT, Economic and Business Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the IPM
- Top five fastest growing Indian pharma market segments
- Top five emerging opportunities within the IPM
- Top pharmaceutical companies within the IPM by market share and revenue
- Multinational penetration into the Indian Pharma Market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top Indian pharmacos
- Economic indicators, trade policy, merchandise and commercial trade statistics
- Gross Domestic Product of India, historic and projection analysis
- Indian economic outlook in comparison to advanced economies

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

- An in-depth understanding of the Indian biopharmaceutical market and it's environment
- Current market facts, figures and product lines of key players in the industry
- An insight into how generic therapeutics will propagate the Indian biopharmaceutical market
- Knowledge of how the Indian biopharma market will integrate into the global healthcare market
- Information on key government policies
- Strategies on how to adapt and restructure current business models to this industry
- Clients may also use referenced tables, figures and data for their own reports and presentations

This report will tell you if the companies mentioned are:

- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity
5.7 Contract Research and Manufacturing Service (CRAMS)
5.8 Indian Pharmaceutical Industry Market
5.9 Evaluation of Market Share by Therapeutic Area
5.10 Indian Biotechnology Industry
5.11 Generic Drug Market
5.12 Vaccine Industry in India
5.13 Key Players
5.14 R&D Spending on the Increase
5.15 Important Market Trends Within the Indian Pharmaceutical Industry

6.0 Indian Pharmaceutical Company Profiles and Financial Data
6.1 Aurobindo Pharma
6.2 Bharat Serums and Vaccines Ltd
6.3 Biocon Biopharmaceuticals
6.4 Cipla
6.5 Divis Laboratories
6.6 Dr Reddy's Laboratories
6.7 Lupin
6.8 Mankind Pharma
6.9 Panacea Biotech
6.10 Piramal Group
6.11 Ranbaxy Laboratories
6.12 Reliance Life Sciences
6.13 Serum Institute of India
6.14 Sun Pharmaceuticals
6.15 Zydus Cadila

7.0 SWOT Analysis of Indian Pharmaceutical Market
7.1 Growth Factors
7.2 Strengths of Indian Pharmaceutical Industry
7.3 Main Weaknesses
7.4 Significant Opportunities within the Indian Pharmaceutical Industry
7.5 Threats and Considerations
8.0 Company Directory and Key People
8.1 Aurobindo Pharma
8.2 Bharat Serums and Vaccines Ltd
8.3 Biocon Biopharmaceuticals
8.4 Cipla
8.5 Divis Laboratories
8.6 Dr Reddy's Laboratories
8.7 Lupin
8.8 Panacea Biotech
8.9 Reliance Life Sciences

9.0 Appendix
9.1 Comprehensive List of Pharmaceutical Company's in India

List of Exhibits
Exhibit 2.1: Key Statistics: India
Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011
Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030
Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India
Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030
Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World
Exhibit 2.7: Cardiovascular Mortality by Indian State
Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India
Exhibit 2.9: Distribution of Cause of Death in Children under Five, India
Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia
Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children
Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present
Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates
Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases
Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-
infection
Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011
Exhibit 2.17: Countries That Have Notified of at Least One XDR-TB Case
Exhibit 2.18: TB Vaccine Development Pipeline 2012
Exhibit 2.19: HIV Prevalence in India 2004-2009
Exhibit 2.20: Routes of HIV Transmission in India
Exhibit 2.21: Global Hepatitis E Virus Endemicity
Exhibit 2.22: Prevalence of Diabetes by Indian Region
Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes
Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes
Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female
Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men
Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India – Women
Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes
Exhibit 2.29: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes
Exhibit 2.30: Five Year Prevalence and Incidence of Top Twenty Cancer's in India
Exhibit 2.31: Mortality Rate (per 100,000) Attributable to Chronic Obstructive Pulmonary Disease Globally
Exhibit 3.1: India's Twelve Year Plan – Key Points in Relation to Science Research and Development
Exhibit 3.2: Budget for Specific Scientific Departments under India's Twelfth Five Year Plan
Exhibit 4.1: World Trade Organisation Basic Indicators on India
Exhibit 4.2: World Trade Organisation Trade Policy of India
Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India
Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India
Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India
Exhibit 4.6: India GDP Figures 2011-2018
Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010
Exhibit 4.8: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013
Exhibit 4.9: Global, Emerging Market & Developing Countries & India Economic Growth Change 2010-2013
Exhibit 4.10: Global, Emerging Market, Developing Countries & Russia Economic Growth Change 2010-2013
Exhibit 4.11: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013
Exhibit 4.12: Global, Emerging Market & Developing Countries & Brazil Economic Growth Change 2010-2013
Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013
Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017
Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013
Exhibit 4.16: France, Germany and Italy Gross Domestic Product per capita Forecast 2010-2017
Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013
Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013
Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017
Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry
Exhibit 5.2: Evolution Timeline of The Indian Pharmaceutical Industry
Exhibit 5.3: Indian Pharmaceutical Industry IPM and Exports 2003-2015
Exhibit 5.4: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015
Exhibit 5.5: Top 50 Exporting Pharmaceutical Companies in India
Exhibit 5.6: Indian Pharmaceutical Industry Formulation Exports 2003-2015
Exhibit 5.7: Indian Pharmaceutical Industry Domestic Formulations 2003-2015
Exhibit 5.8: Indian Pharmaceutical Industry Domestic Formulations 2003-2015
Exhibit 5.9: Current Trends of the Global Biosimilar Market
Exhibit 5.10: Main Therapeutic Areas of the Future Biosimilar Market
Exhibit 5.11: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry
Exhibit 5.12: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry
Exhibit 5.14: Drivers and Resistors of the Indian CRAMS/CMO Industry
Exhibit 5.15: Advantages of Contract Research Organizations in India
Exhibit 5.16: Challenges of Contract Research Organizations in India
Exhibit 5.17: Areas of Growth and Potential for Indian Contract Research Organisation's
Exhibit 5.18: Indian Pharmaceutical Market Revenue 2005-2020
Exhibit 5.19: Generic Drug, Over the Counter and Patened Drug Sub-Market Revenue Share
Exhibit 5.20: India's Pharmaceutical Market Share by Value in the Asia-Pacific Region
Exhibit 5.21: Leading Players of the Indian Pharmaceutical Market
Exhibit 5.22: Top 20 Biotechnology Companies in India by Revenue FY2013
Exhibit 5.23: India - Significant Economic Indicators
Exhibit 5.24: Positive Factors Influencing the Indian Pharmaceutical Market
Exhibit 5.25: Quantitative Market Share of Acute and Chronic Therapy in India
Exhibit 5.26: Multinational Company Penetration into Indian Pharmaceutical Market
Exhibit 5.27: Key Factors Influencing Leading Player Position in India Pharma Market
Exhibit 5.28: Partnerships Between International Pharmaco's and Domestic API Partners
Exhibit 5.29: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013-Table Format
Exhibit 5.30: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013- Pie Chart Format
Exhibit 5.31: Indian Pharmaceutical Market Share (%) by Therapeutic Area
Exhibit 5.32: Top Five Fastest Growing Indian Pharma Market Segments
Exhibit 5.33: Top Biotechnology Companies by Revenue FY2013 (Barchart)
Exhibit 5.34: Top 20 Biotechnology Companies in India by Revenue FY2013 Table
Exhibit 5.35: Top Five Emerging Opportunities within the Indian Pharmaceutical Market
Exhibit 5.36: Top Five Indian Vaccine Manufacturers
Exhibit 5.37: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue
Exhibit 5.38: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market
Exhibit 5.39: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012
Exhibit 5.40: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2013
Exhibit 5.41: R&D Investment Comparison of Top Indian Pharmaco's 2010 Vs 2013
Exhibit 5.42: R&D Investment Table of Top Indian Pharmaco's 2010 Vs 2013
Exhibit 5.43: Investments, Acquisitions and Joint Ventures Between International and Indian Pharmacos
Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest
Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation
Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations
Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest
Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio
Exhibit 6.6: Aurobindo Pharma Osteoarthritis Therapeutic Product Portfolio
Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio
Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio
Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio
Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio
Exhibit 6.11: Aurobindo Pharma Antisteoporotic Product Portfolio
Exhibit 6.12: Aurobindo Pharma Alzheimer's Product Portfolio
Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio
Exhibit 6.14: Aurobindo Pharma Antiasthmatic Product Portfolio
Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio
Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio
Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio
Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio
Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio
Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio
Exhibit 6.21: Aurobindo Pharma Consolidated Revenue FY2010-FY2013
Exhibit 6.22: Aurobindo Pharma Revenue Breakdown: Formulation and API Sales FY2013
Exhibit 6.23: Aurobindo Pharma Subsidiary Companies
Exhibit 6.24: Aurobindo Pharma Long Term Growth Strategies
Exhibit 6.25: Bharat Serums and Vaccines Significant Milestones
Exhibit 6.26: Bharat Serums and Vaccines Range of Products
Exhibit 6.27: Bharat Serums and Vaccines Plasma Serum Product Portfolio
Exhibit 6.28: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio
Exhibit 6.29: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio
Exhibit 6.30: Bharat Serums and Vaccines Cardiovascular Product Portfolio
Exhibit 6.31: Bharat Serums and Vaccines Anti-microbial Product Portfolio
Exhibit 6.32: Bharat Serums and Vaccines Anti-fungal Product Portfolio
Exhibit 6.33: Bharat Serums and Vaccines Anaesthesia Product Portfolio
Exhibit 6.34: Bharat Serums and Vaccines Hormone Product Portfolio
Exhibit 6.35: Biocon Biopharmaceuticals Business Outline
Exhibit 6.36: Biocon Biopharmaceuticals Five Key Business Areas
Exhibit 6.37: Biocon Biopharmaceuticals Subsidiary Companies
Exhibit 6.38: Biocon Biopharmaceuticals Important Milestones
Exhibit 6.39: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas
Exhibit 6.40: Biocon Biopharmaceuticals Active Biological Product Areas
Exhibit 6.41: Biocon Biopharmaceuticals Diabetes Branded Formulations
Exhibit 6.42: Biocon Biopharmaceuticals Oncology Branded Therapeutics
Exhibit 6.43: Biocon Biopharmaceuticals Nephrology Branded Therapeutics
Exhibit 6.44: Biocon Biopharmaceuticals Cardiology Branded Therapeutics
Exhibit 6.45: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics
Exhibit 6.46: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics
Exhibit 6.47: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics
Exhibit 6.48: Biocon Biopharmaceuticals – Syngene Service Platform
Exhibit 6.49: Biocon Biopharmaceuticals – Clinigene Service Platform
Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2014
Exhibit 6.51: Biocon Biopharmaceuticals Revenue 2008-2014
Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2014
Exhibit 6.53: Biocon Biopharmaceuticals Profits from Operations 2008-2014
Exhibit 6.54: Cipla Important Milestones
Exhibit 6.55: Cipla Main Therapeutics Areas of Interest
Exhibit 6.56: Cipla Export Market Share FY2012-2013
Exhibit 6.57: Cipla Sales and Other Income Exhibits 2003-2013
Exhibit 6.58: Cipla Profit after Tax Figures 2003-2013
Exhibit 6.59: Cipla Significant Product Launches
Exhibit 6.60: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches
Exhibit 6.61: Divis Laboratories Important Milestones
Exhibit 6.62: Divis Laboratories Product Category Portfolio
Exhibit 6.63: Divis Laboratories Product List
Exhibit 6.64: Divis Laboratories Income From Operations 2006-2013
Exhibit 6.65: Divis Laboratories Future Pipeline Portfolio
Exhibit 6.66: Dr Reddy's Therapeutic Areas of Interest
Exhibit 6.67: Dr Reddy's Laboratories – Important Milestones
Exhibit 6.68: Dr Reddy's Labs Top Active Pharmaceutical Ingredients
Exhibit 6.69: Dr Reddy's Labs Top Brands in India
Exhibit 6.70: Dr Reddy's Laboratories Annual Revenue Figures 2003-2014
Exhibit 6.71: Dr Reddy's Laboratories Historical Revenue Figures 2006-2014 (Global)
Exhibit 6.72: Dr Reddy's Laboratories Geographical Revenue Percentage
Exhibit 6.73: Dr Reddy's Key Brand Revenue in Russia 2011-2012
Exhibit 6.74: Dr Reddy's Key Brand Revenue in India 2011-2012
Exhibit 6.75: Dr Reddy's Therapeutic Agents and Classes undergoing Clinical Trials
Exhibit 6.76: Lupin Significant Milestones
Exhibit 6.77: Lupin Ltd Formulations Product Portfolio
Exhibit 6.78: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio
Exhibit 6.79: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution
Exhibit 6.80: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012
Exhibit 6.81: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution
Exhibit 6.82: Lupin Ltd Geographic Breakdown of Revenue
Exhibit 6.83: Lupin Ltd Net Global Sales 2008-2014
Exhibit 6.84: Lupin Ltd Profit Before Tax 2008-2013
Exhibit 6.85: Lupin Ltd Formulation Sales 2006-2013 Indian Market
Exhibit 6.86: Lupin Ltd Top Product Brands in the Indian Market and Ranking
Exhibit 6.87: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth
Exhibit 6.88: Lupin Pharma Key Products and Rank in the Indian Market
Exhibit 6.89: Lupin Respira Key Products and Rank in the Indian Market
Exhibit 6.90: Lupin Endeavour Key Products and Rank in the Indian Market
Exhibit 6.91: Lupin Maxter Key Products and Rank in the Indian Market
Exhibit 6.92: Lupin Pinnacle CVS Key Products and Rank in the Indian Market
Exhibit 6.93: Lupin Diabetes Care Key Products and Rank in the Indian Market
Exhibit 6.94: Lupin Mindvision Key Products and Rank in the Indian Market
Exhibit 6.95: Lupin Ikonic Key Products and Rank in the Indian Market
Exhibit 6.97: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market
Exhibit 6.98: Lupin Ltd Percentage Market Share within US Generics Market
Exhibit 6.100: Lupin Ltd Division of Sales by Therapeutic Area
Exhibit 6.101: Lupin Ltd Advanced Drug Delivery System Platform Portfolio
Exhibit 6.102: Lupin Ltd Research and Development Areas of Expertise
Exhibit 6.103: Mankind Pharma Company Divisions
Exhibit 6.104: Mankind Pharma Key Milestones
Exhibit 6.105: Mankind Pharma Therapeutic Areas of Interest
Exhibit 6.106: Mankind Pharma Prescription Product Areas
Exhibit 8.23: Lupin Board of Directors
Exhibit 8.24: Lupin Key Management Players
Exhibit 8.25: Lupin Ltd General Contact Details
Exhibit 8.26: Panacea Biotech – Whole Time Directors
Exhibit 8.27: Panacea Biotech – Independent Directors
Exhibit 8.28: Panacea Biotech – Investor Contact Details
Exhibit 8.29: Panacea Biotech – General Contact Details
Exhibit 8.30: Reliance Life Sciences – General Contact Details

Ordering:  
Order Online - [http://www.researchandmarkets.com/reports/2887502/](http://www.researchandmarkets.com/reports/2887502/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMs), Biosimilars, Generics & Vaccines
- Web Address: http://www.researchandmarkets.com/reports/2887502/
- Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Description</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF - Subscription) -</td>
<td>USD 3400</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users:</td>
<td>USD 6800</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp